Novartis unwavering in support one year on from the start of the war in Ukraine Novartis has marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while the unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines. Novartis, a global medicines company, has […]
Novartis supports Ukraine one year on Read More »
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has announced that the US Food and Drug Administration (US FDA) has accepted its Biologics License Application (BLA) for proposed biosimilar denosumab. The application includes all indications covered by the reference medicines Prolia® (denosumab)
US FDA accepts Sandoz Biologics License Application Read More »
Novartis provides update on Phase III STAND trial assessing crizanlizumab The preliminary results from the ongoing global phase III study STAND indicate no statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg and placebo in annualized rates of vaso-occlusive crises (pain crises) leading to a healthcare visit over the first-year post randomization. These findings are
Update on Phase III STAND trial assessing crizanlizumab Read More »
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries Pfizer Inc. has announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has
Pfizer Expands ‘An Accord for a Healthier World’ Product Read More »
U.S. FDA Accepts for Review the Biologics License Application (BLA) for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY for the prevention of
U.S. FDA Accepts for Review the BLA for MenABCWY Read More »
